Article
Structural and Physical Basis for Anti-IgE Therapy.
Scientific reports - 26 Jun 2015
Wright Jon D, Chu Hsing-Mao, Huang Chun-Hsiang, Ma Che, Chang Tse Wen, Lim Carmay
Abstract excerpt
Omalizumab, an anti-IgE antibody, used to treat severe allergic asthma and chronic idiopathic urticaria, binds to IgE in blood or membrane-bound on B lymphocytes but not to IgE bound to its high (FcεRI) or low (CD23) affinity receptor. Mutagenesis studies indicate overlapping FcεRI and omalizumab-binding sites in the Cε3 domain, but crystallographic studies show FcεRI and CD23-binding sites that are far apart, so...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.